TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Employee Related Liabilities
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Employee Related Liabilities of -$5.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $3.36M, a 100.12% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$9.25M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $4.23M, a 6.00% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $1.94M, a 40.85% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for fiscal 2025 was $1.96M, a 24.13% decline from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for fiscal 2024 was $2.58M, a 66.63% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for fiscal 2023 was $7.73M, a 183.94% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in employee related liabilities for fiscal 2022 was $2.72M, a 54.78% increase from fiscal 2021.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.89M 10-Q · filed 2026-08-06 | -$1.66M derived: sum of 3 quarters · filed 2026-08-06 | $276.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$9.25M 10-Q · filed 2026-05-06 | -$5.02M derived: sum of 2 quarters · filed 2026-05-06 | -$3.08M derived: sum of 3 quarters · filed 2026-05-06 | -$1.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $6.17M derived: sum of 2 quarters · filed 2026-02-23 | $7.85M derived: sum of 3 quarters · filed 2026-08-06 | $1.96M 10-K · filed 2026-02-23 |
| 2025-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.62M derived: sum of 2 quarters · filed 2026-08-06 | -$2.27M 10-Q · filed 2025-11-04 | $2.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.21M 10-Q · filed 2026-08-06 | $286.00K derived: sum of 3 quarters · filed 2026-08-06 | $3.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$5.89M 10-Q · filed 2026-05-06 | -$1.39M derived: sum of 2 quarters · filed 2026-05-06 | $1.89M derived: sum of 3 quarters · filed 2026-05-06 | $3.98M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $7.78M derived: sum of 2 quarters · filed 2026-02-23 | $9.87M derived: sum of 3 quarters · filed 2026-02-23 | $2.58M 10-K · filed 2026-02-23 |
| 2024-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.37M derived: sum of 2 quarters · filed 2025-11-04 | -$1.92M 10-Q · filed 2025-11-04 | $3.43M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$5.20M 10-Q · filed 2025-08-06 | $147.00K derived: sum of 3 quarters · filed 2026-02-23 | $2.74M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$7.29M 10-Q · filed 2025-05-01 | -$1.94M derived: sum of 2 quarters · filed 2026-02-23 | $652.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.75M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $7.94M derived: sum of 2 quarters · filed 2026-02-23 | $9.04M derived: sum of 3 quarters · filed 2026-02-23 | $7.73M 10-K · filed 2026-02-23 |
| 2023-09-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.69M derived: sum of 2 quarters · filed 2024-11-13 | $2.38M 10-Q · filed 2024-11-13 | $3.81M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$213.00K 10-Q · filed 2024-08-08 | $1.21M derived: sum of 3 quarters · filed 2025-02-25 | $2.53M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$1.31M 10-Q · filed 2024-05-08 | $114.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.43M derived: sum of 3 quarters · filed 2025-02-25 | $2.40M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $2.74M derived: sum of 2 quarters · filed 2025-02-25 | $3.71M derived: sum of 3 quarters · filed 2025-02-25 | $2.72M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.29M derived: sum of 2 quarters · filed 2023-11-09 | $1.29M 10-Q · filed 2023-11-09 | $1.85M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $975.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$18.00K 10-Q · filed 2023-08-10 | $534.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.31M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$993.00K 10-Q · filed 2023-05-09 | -$441.00K derived: sum of 2 quarters · filed 2023-05-09 | $335.00K derived: sum of 3 quarters · filed 2023-05-09 | $1.12M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $552.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $1.33M derived: sum of 2 quarters · filed 2023-03-17 | $2.11M derived: sum of 3 quarters · filed 2023-03-17 | $1.76M 10-K · filed 2023-03-17 |
| 2021-09-30 | $776.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.56M derived: sum of 2 quarters · filed 2022-11-09 | $1.21M 10-Q · filed 2022-11-09 | $1.73M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $785.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $430.00K 10-Q · filed 2022-08-11 | $950.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.20M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$355.00K 10-Q · filed 2022-05-11 | $165.00K derived: sum of 2 quarters · filed 2022-05-11 | $413.00K derived: sum of 3 quarters · filed 2022-05-11 | $551.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $520.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $768.00K derived: sum of 2 quarters · filed 2022-03-14 | $906.00K derived: sum of 3 quarters · filed 2022-03-14 | $741.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $386.00K derived: sum of 2 quarters · filed 2021-11-10 | $221.00K 10-Q · filed 2021-11-10 | $490.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$27.00K 10-Q · filed 2021-08-05 | $242.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$165.00K 10-Q · filed 2021-05-11 | $104.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $296.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $27.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |